Achillion Pharmaceuticals, Inc.
Records under this name other than the patents Achillion Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 51 patents it holds.
Back to Achillion Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,106,563 | Ether Compounds for Treatment of Complement Mediated Disorders Lapsed on the fee record Ended Oct 23, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 23, 2026 | Low confidence |
| US 10,100,072 | Phosphonate Compounds for Treatment of Complement Mediated Disorders Lapsed on the fee record Ended Oct 16, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 16, 2026 | Low confidence |
| US 10,092,547 | Substituted Aliphanes, Cyclophanes, Heteraphanes, Heterophanes, Hetero-Heteraphanes and Metallocenes Useful for Treating HCV Infections Lapsed on the fee record Ended Oct 9, 2026 · High confidence | Lapsed on the fee record | Ended Oct 9, 2026 | High confidence |
| US 10,092,584 | Compounds for the Treatment of Medical Disorders Lapsed on the fee record Ended Oct 9, 2026 · High confidence | Lapsed on the fee record | Ended Oct 9, 2026 | High confidence |
| US 10,087,203 | Compounds for Treatment of Complement Mediated Disorders Lapsed on the fee record Ended Oct 2, 2026 · High confidence | Lapsed on the fee record | Ended Oct 2, 2026 | High confidence |
| US 8,809,313 | Substituted Aliphanes, Cyclophanes, Heteraphanes, Heterophanes, Hetero-Heteraphanes and Metallocenes Useful for Treating HCV Infections Lapsed on the fee record Ended Aug 19, 2026 · High confidence | Lapsed on the fee record | Ended Aug 19, 2026 | High confidence |
| US 8,946,422 | 8-Methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and Related Compounds as Anti-Infective Agents Term ended Ended no later than Jul 27, 2026 · Low confidence | Term ended | Ended no later than Jul 27, 2026 | Low confidence |
| US 8,785,378 | Macrocyclic Peptides as Inhibitors of Viral Replication Lapsed on the fee record Ended Jul 22, 2026 · High confidence | Lapsed on the fee record | Ended Jul 22, 2026 | High confidence |
| US 10,005,802 | Amide Compounds for Treatment of Complement Mediated Disorders Lapsed on the fee record Ended Jun 26, 2026 · Medium confidence | Lapsed on the fee record | Ended Jun 26, 2026 | Medium confidence |
| US 10,000,516 | Phosphonate compounds for treatment of medical disorders Lapsed on the fee record Ended Jun 19, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 19, 2026 | USPTO record |